254 related articles for article (PubMed ID: 3097567)
1. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
[TBL] [Abstract][Full Text] [Related]
2. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Neuwelt EA; Hill SA; Frenkel EP
Neurosurgery; 1984 Sep; 15(3):362-6. PubMed ID: 6090973
[TBL] [Abstract][Full Text] [Related]
3. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review.
Gumerlock MK; Belshe BD; Madsen R; Watts C
J Neurooncol; 1992 Jan; 12(1):33-46. PubMed ID: 1541977
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.
Doolittle ND; Miner ME; Hall WA; Siegal T; Jerome E; Osztie E; McAllister LD; Bubalo JS; Kraemer DF; Fortin D; Nixon R; Muldoon LL; Neuwelt EA
Cancer; 2000 Feb; 88(3):637-47. PubMed ID: 10649259
[TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors.
Miyagami M; Tsubokawa T; Tazoe M; Kagawa Y
Neurol Med Chir (Tokyo); 1990 Aug; 30(8):582-90. PubMed ID: 1703636
[TBL] [Abstract][Full Text] [Related]
7. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.
Neuwelt EA; Dahlborg SA
J Neurooncol; 1987; 4(3):195-207. PubMed ID: 3104548
[TBL] [Abstract][Full Text] [Related]
9. Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomas.
Heimberger K; Samec P; Binder H; Podreka I; Reisner T; Deecke L; Horaczek A; Dittrich C; Steger G; Zimpfer M
Acta Radiol Suppl; 1986; 369():223-6. PubMed ID: 2980457
[TBL] [Abstract][Full Text] [Related]
10. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
Miyagami M; Kagawa Y; Tsubokawa T
No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
[TBL] [Abstract][Full Text] [Related]
11. Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
Xue H; Wang H; Kong L; Zhou H
Chin Med J (Engl); 1998 Aug; 111(8):751-3. PubMed ID: 11245034
[TBL] [Abstract][Full Text] [Related]
12. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
Neuwelt EA; Rapoport SI
Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
[TBL] [Abstract][Full Text] [Related]
13. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
[TBL] [Abstract][Full Text] [Related]
14. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.
Neuwelt EA; Balaban E; Diehl J; Hill S; Frenkel E
Neurosurgery; 1983 Jun; 12(6):662-71. PubMed ID: 6410302
[TBL] [Abstract][Full Text] [Related]
16. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
[TBL] [Abstract][Full Text] [Related]
17. Intra-arterial chemotherapy following blood-brain barrier disruption in a patient with malignant glioma.
Hill SA; Neuwelt EA
J Neurosurg Nurs; 1982 Apr; 14(2):94-7. PubMed ID: 6811704
[No Abstract] [Full Text] [Related]
18. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.
Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP
Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926
[TBL] [Abstract][Full Text] [Related]
19. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
[TBL] [Abstract][Full Text] [Related]
20. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
